{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"738","value":"1240"},{"comment":"Not calculable","groupId":"OG001","spread":"NA","value":"1570"}]}],"title":"Day 1 Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1040","value":"1620"},{"comment":"Not calculable","groupId":"OG001","spread":"NA","value":"2260"}]}],"title":"Day 3 Cycle 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"description":"Cmax of trilaciclib in plasma was determined from individual concentration-time data by non-compartmental analysis methods. The actual sampling times in relation to dosing were used. For estimation of Cmax, a concentration that was below the limit of quantification (BLQ) was assigned a value of zero if it occurred in a profile before the first measurable concentration. If a BLQ value occurred after a measurable concentration in a profile, and was followed by a value above the lower limit of quantification, then the BLQ was treated as missing data. If a BLQ value occurred at the end of the collection interval (after the last quantifiable concentration) it was treated as missing data. If two BLQ values occurred in succession after Cmax, the profile was deemed to have terminated at the first BLQ value and any subsequent concentrations were omitted.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received trilaciclib 200 mg/m\\^2 administered intravenously (IV) once daily on Days 1 to 3 of each 21-day E/P chemotherapy cycle.","id":"OG000","title":"Part 1: Cohort 1 Trilaciclib 200 mg/m^2"},{"description":"Participants received trilaciclib 240 mg/m\\^2 administered IV once daily on Days 1 to 3 of each 21-day E/P chemotherapy cycle.","id":"OG001","title":"Part 1: Cohort 2 Trilaciclib 240mg/m^2"}],"paramType":"MEAN","populationDescription":"Pharmacokinetic (PK) analysis set - included all participants with evaluable PK profiles for both treatments and analytes.","reportingStatus":"POSTED","timeFrame":"Days 1 and 3 of Cycle 1 for a 21-day cycle","title":"Maximum Observed Plasma Concentration (Cmax) of Trilaciclib in Cycle 1, Part 1","type":"SECONDARY","unitOfMeasure":"ng/mL"}